LY 03005

Drug Profile

LY 03005

Alternative Names: 4-Methylbenzoate desvenlafaxine hydrochloride; Desvenlafaxine prodrug; LY03005

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Luye Pharma Group
  • Class Antidepressants; Benzoates; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Major depressive disorder

Most Recent Events

  • 01 Dec 2016 Luye Pharma initiates a phase I bioavailability trial in Healthy volunteers in USA (PO) (NCT02988024)
  • 01 Mar 2015 Luye Pharma completes a phase I trial in Healthy volunteers in USA (NCT02271412)
  • 01 Oct 2014 Luye Pharma initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT02271412)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top